secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-10-30T21:15:18+00:00
Accession:  0001104659-26-120737
Event type: m_and_a
Sentiment:  negative
Materiality: 0.88
Item codes: 2.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BioXcel closes $57.5M Teva asset sale; CEO, CFO and two other officers terminated; renaming to BX Liquidation
--------------------------------------------------------------------------------

- Teva paid $57.5M upfront cash (against which its $5.75M deposit was credited) for IGALMI (dexmedetomidine)/BXCL501 neuroscience assets; BXCL701 and BXCL702 were retained.
- Additional consideration: up to $67.5M development milestone on FDA approval of the IGALMI at-home-use sNDA, plus up to $20M in sales milestones at $250M and $500M annual net sales.
- Board terminated CEO Vimal Mehta, CFO Richard Steinhart, CSO Frank Yocca and CLO Javier Rodriguez effective 5 p.m. Oct 31, 2026; Mehta stays a director at $5,000/month.
- Samir Saleem, Chief Restructuring Officer, was named President, Secretary and principal executive officer; the company will be renamed BX Liquidation, Inc. ahead of wind-down.
- Sale closed Oct 26, 2026 under the Court's Oct 21 Sale Order after no qualifying bids beat Teva's stalking-horse APA; proceeds repaid the debtor-in-possession facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926120737/0001104659-26-120737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926120737/tm2624733d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-120737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer